Request access No cost Early Access limited licenses for AVM for cBioPortal are available for Windows users.
AlphaVision® for Medical (AVM) is a powerful software platform for blending (integrating) multiple data sets into a single actionable 3D Landscape. Through interactive data shaping, the user is empowered to conduct exploratory analysis and ask questions of the data with immediate answers. For more information, see Technology.
| cBioPortal enables many different types of group comparisons, with various data tables. For example, comparing Genomic Alterations between two samples with and without alterations in EGR1. |
![]() |
| With AVM for cBioPortal installed, launch directly from a cBioPortal data table to see your data in AVM.
This cBioPortal experience is enhanced by allowing you to see all the data in these tables in an interactive 3D Landscape for easy exploration.
Intuitive: Navigate through a familar interface and inspect individual data points in biological context. | ![]() |
AVM’s data shaping tools allow for both reducing and rearranging the data, to enable answering biological questions dynamically.
Reduce: Use filters and aggregation, as well as a powerful formula system to compute on-the-fly. |
|
With genomic data, you are able to run pathway analysis and see pathways side-by-side with the loaded data on-the-fly. |
|
AVM’s patented Data Model blends multiple types of data into a unified, comprehensive representation on-the-fly. For example, blending CNA, Methylation, mRNA and variants data by gene to provide insight into how specific mutations correlate with other biological processes.
Powerful: Drill-down to any dataset or dimension for detailed analysis. |
![]() |
“Aqumin, through the power of graphical representation of molecular data using their highly innovative AVM software program, highlighted for my lab a potentially important candidate biomarker. This gene’s expression pattern, blended on-the-fly in AVM with other Omics data, stood out instantly in AVM’s 3D landscape and immediately drew our attention as biologically significant to our pancreatic cancer research program. The program dramatically accelerated our discovery efforts and we are continuing to use AVM to identify novel hits that we will validate in the lab for diagnostic, prognostic, and predictive biomarker discovery.”
Kenneth R. Shroyer, M.D., Ph.D. Renaissance School of Medicine